Targeting of tumor endothelial cells combining 2 Gy/day of X-ray with Everolimus is the effective modality for overcoming clinically relevant radioresistant tumors.
Bottom Line: Radiotherapy is widely used to treat cancer because it has the advantage of physically and functionally conserving the affected organ.To improve radiotherapy and investigate the molecular mechanisms of cellular radioresistance, we established a clinically relevant radioresistant (CRR) cell line, SAS-R, from SAS cells.We conclude that FR combined with Everolimus may be an effective modality to overcome radioresistant tumors via targeting tumor ECs.
Affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, 980-8575, Japan.Show MeSH
Related in: MedlinePlus
Mentions: Until 10 days after each treatment, the tumor volume of SAS increased; thereafter, it gradually decreased in all the treatment groups with FR, FR with Everolimus, and Everolimus alone during the experimental period. The volume of SAS tumors with vehicle continuously increased (Fig. 4A). On the other hand, until 10 days after Everolimus treatment the tumor volume of SAS-R increased followed by gradual decrease, but the tumor volume remained larger than that at the beginning. SAS-R tumors grew by 5 days of the treatment with Everolimus and FR. Thereafter, the tumor volume shrunk. On day 30, the volume of SAS-R tumors treated with FR and Everolimus was smaller than the initial volume (day 0). The most effective treatment for the control of SAS-R tumors was the combination of FR with Everolimus.
Affiliation: Department of Pathology, Institute of Development, Aging and Cancer, Tohoku University, Sendai, Miyagi, 980-8575, Japan.